Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes.

Leibowitz MS, Andrade Filho PA, Ferrone S, Ferris RL.

Cancer Immunol Immunother. 2011 Apr;60(4):525-35. doi: 10.1007/s00262-010-0961-7.

2.
3.

Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer.

Ferris RL, Whiteside TL, Ferrone S.

Clin Cancer Res. 2006 Jul 1;12(13):3890-5. Review.

4.

TAP expression level in tumor cells defines the nature and processing of MHC class I peptides for recognition by tumor-specific cytotoxic T lymphocytes.

El Hage F, Durgeau A, Mami-Chouaib F.

Ann N Y Acad Sci. 2013 Apr;1283:75-80. doi: 10.1111/j.1749-6632.2012.06777.x. Review.

PMID:
23302073
5.

T cell-tumor interaction directs the development of immunotherapies in head and neck cancer.

Albers AE, Strauss L, Liao T, Hoffmann TK, Kaufmann AM.

Clin Dev Immunol. 2010;2010:236378. doi: 10.1155/2010/236378. Review.

6.

A novel category of antigens enabling CTL immunity to tumor escape variants: Cinderella antigens.

Seidel UJ, Oliveira CC, Lampen MH, Hall Tv.

Cancer Immunol Immunother. 2012 Jan;61(1):119-25. doi: 10.1007/s00262-011-1160-x. Review.

7.

Escape from IFN-γ-dependent immunosurveillance in tumorigenesis.

Lin CF, Lin CM, Lee KY, Wu SY, Feng PH, Chen KY, Chuang HC, Chen CL, Wang YC, Tseng PC, Tsai TT.

J Biomed Sci. 2017 Feb 1;24(1):10. doi: 10.1186/s12929-017-0317-0. Review.

Supplemental Content

Support Center